METTL5、VIRMA在肝细胞肝癌中的表达及与临床预后的关系  

Expression of METTL5 and VIRMA in hepatocellular carcinoma and their relationship with clinical prognosis

作　　者：陈宏[1] 刘磊 周华友[2] 杨华[1] 杨瑞[1] CHEN Hong;LIU Lei;ZHOU Huayou;YANG Hua;YANG Rui(Department of Hepatobiliary Pancreatic Splenic Surgery,Shaanxi,723000,China;Department of General Surgery,Hanzhong Central Hospital,Shaanxi,723000,China)

机构地区：[1]汉中市中心医院肝胆胰脾外科,陕西汉中723000 [2]汉中市中心医院普通外科,陕西汉中723000

出　　处：《国际检验医学杂志》2025年第9期1060-1065,共6页International Journal of Laboratory Medicine

基　　金：陕西省卫生健康科研基金项目(2019D0057)。

摘　　要：目的研究肝细胞肝癌(HCC)中甲基转移酶样蛋白5(METTL5)、病毒样m^(6)A甲基转化酶(VIRMA)的表达及与临床预后的关系。方法选取2018年3月至2021年3月就诊于该院的89例HCC患者。应用免疫组化和荧光定量PCR检测组织METTL5、VIRMA蛋白和m RNA表达。利用Kaplan-Meier曲线和Cox回归分析METTL5、VIRMA蛋白对HCC预后的影响。结果HCC癌组织METTL5 m RNA(3.23±0.55 vs.0.61±0.20),VIRMA m RNA(2.97±0.42 vs.0.58±0.17)高于癌旁组织,差异有统计学意义(t=42.234、49.762,均P<0.001)。METTL5、VIRMA蛋白位于细胞质和细胞膜,部分位于细胞核。HCC癌组织METTL5[71.91%(64/89)vs.5.62%(5/89)]、VIRMA[69.66%(62/89)vs.6.74%(6/89)]阳性率高于癌旁组织,差异有统计学意义(χ^(2)=82.385、74.627,P<0.001,P=0.001)。HCC中METTL5、VIRMA蛋白表达与肝癌分期标准(CNLC)、肿瘤最大径及血管侵犯有关,CNLC分期Ⅱ~Ⅲ期、肿瘤最大径≥5 cm及血管侵犯的HCC癌组织中METTL5、VIRMA蛋白阳性率较高(均P<0.05)。METTL5阳性组和阴性组3年生存率为34.88%(15/43),67.39%(31/46),差异有统计学意义(Log-rankχ^(2)=7.893,P=0.005)。VIRMA阳性组和阴性组3年生存率为36.36%(16/44)、66.67%(30/45),差异有统计学意义(Log-rankχ^(2)=9.828,P=0.002)。CNLC分期Ⅱ~Ⅲ期、肿瘤最大径≥5 cm、血管侵犯、METTL5阳性、VIRMA阳性是影响HCC患者不良预后的危险因素。结论HCC中METTL5、VIRMA表达上调,均与CNLC分期Ⅱ~Ⅲ期、肿瘤最大径及血管侵犯有关,是评估HCC预后的肿瘤标志物。Objective To investigate the expression of methyltransferase like protein 5(METTL5)and Viral like m 6A methyltransferase associated(VIRMA)in hepatocellular carcinoma(HCC)and their relationship with clinical prognosis.Methods A total of 89 HCC patients who visited the hospital from March 2018 to March 2021 were enrolled in the study.Immunohistochemistry and fluorescence quantitative PCR were conducted to analyze the expression of METTL5,VIRMA protein and mRNA in tissues.Kaplan-Meier curve and COX regression were used to analyze the impact of METTL5 and VIRMA proteins on the prognosis of HCC.Results The METTL5 mRNA(3.23±0.55 vs.0.61±0.20)and VIRMA mRNA(2.97±0.42 vs.0.58±0.17)in HCC cancer tissue were higher than those in adjacent tissues,and the differences were statistically significant(t=42.234,49.762,both P<0.001).METTL5 and VIRMA proteins were located in the cytoplasm and cell membrane,with some in the nucleus.The positive rates of METTL5[71.91%(64/89)vs.5.62%(5/89)]and VIRMA[69.66%(62/89)vs.6.74%(6/89)]in HCC cancer tissues were higher than those in adjacent tissues,and the differences were statistically significant(χ^(2)=82.385,74.627,P<0.001,P=0.001).The expression of METTL5 and VIRMA proteins in HCC were related to China Liver Cancer Staging(CNLC)stages,maximum tumor diameter,and vascular invasion,and the positive rates of METTL5 and VIRMA proteins were higher in HCC cancer tissues with CNLC stageⅡ-Ⅲ,maximum tumor diameter≥5 cm,and vascular invasion(P<0.05).The 3-year survival rates of METTL5 positive and negative groups were 34.88%(15/43)and 67.39%(31/46),with statistically significant differences(Log-rankχ^(2)=7.893,P=0.005).The 3-year survival rates of the VIRMA positive and negative groups were 36.36%(16/44)and 66.67%(30/45),with statistically significant differences(Log-rankχ^(2)=9.828,P=0.002).CNLC staging stagesⅡ-Ⅲ,maximum tumor diameter≥5 cm,vascular invasion,METTL5 positivity,and VIRMA positivity were risk factors for poor prognosis in HCC patients(P<0.05).Conclusion The upregula

关 键 词：肝细胞肝癌 甲基转移酶样蛋白5 病毒样m^(6)A甲基转化酶 预后 

分 类 号：R735.7[医药卫生—肿瘤] R730.43[医药卫生—临床医学]